MCA Stability Tool

Find stability recommendations for tablets and capsules.

Product Search

Stability Notes

Soluble tablets - unsuitable for MCA.

Provenance

This compatibility recommendation is derived from generic co-codamol 8mg/500mg effervescent tablets.

Stability Notes

No special precautions for storage for up to 28 days only based on manufacturer's stability data.

Provenance

This compatibility recommendation is derived from Januvia 25mg tablets (Merck Sharp & Dohme (UK) Ltd).

Stability Notes

No special precautions for storage for up to 28 days only based on manufacturer's stability data.

Provenance

This compatibility recommendation is derived from Januvia 50mg tablets (Merck Sharp & Dohme (UK) Ltd).

Stability Notes

No special precautions for storage for up to 28 days only based on manufacturer's stability data.

Provenance

This compatibility recommendation is derived from Januvia 100mg tablets (Merck Sharp & Dohme (UK) Ltd).

Stability Notes

Soluble tablets - unsuitable for MCA.

Provenance

This compatibility recommendation is derived from Solpadol 30mg/500mg effervescent tablets (Sanofi) and generic co-codamol 30mg/500mg effervescent tablets.

Stability Notes

No special requirements for storage.

Provenance

This compatibility recommendation is derived from Vimpat 50mg tablets (UCB Pharma Ltd).

Stability Notes

No special requirements for storage.

Provenance

This compatibility recommendation is derived from Vimpat 200mg tablets (UCB Pharma Ltd).

Stability Notes

Store in an airtight container and protect from light.

Provenance

This compatibility recommendation is derived from Baraclude 0.5mg tablets (Bristol-Myers Squibb Pharmaceuticals Ltd).

Print this list

Medicines under this category are suitable for use inside MCAs, although this is likely to be an off-label use.
Medicines under this category can theoretically be used inside an MCA; however, mitigations may need to be considered.
Medicines under this category are not suitable for use inside MCAs.
We do not have stability information for these medicines and therefore cannot make a recommendation on suitability in an MCA.